AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 237 filers reported holding AMICUS THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $55,481 | -12.7% | 4,562,567 | -9.9% | 2.38% | +20.7% |
| Q2 2023 | $63,586 | +62.6% | 5,062,567 | +43.6% | 1.97% | -15.2% |
| Q1 2023 | $39,108 | -19.9% | 3,526,407 | -11.8% | 2.32% | -14.7% |
| Q4 2022 | $48,840 | -99.9% | 4,000,000 | 0.0% | 2.73% | +53.0% |
| Q3 2022 | $41,760,000 | -2.8% | 4,000,000 | 0.0% | 1.78% | -22.4% |
| Q2 2022 | $42,960,000 | +13.4% | 4,000,000 | 0.0% | 2.30% | +44.7% |
| Q1 2022 | $37,880,000 | -45.3% | 4,000,000 | -33.3% | 1.59% | -15.6% |
| Q4 2021 | $69,300,000 | +8.4% | 6,000,000 | -10.4% | 1.88% | +31.4% |
| Q3 2021 | $63,956,000 | +76.9% | 6,696,955 | +78.6% | 1.43% | +95.0% |
| Q2 2021 | $36,150,000 | -2.4% | 3,750,000 | 0.0% | 0.73% | +12.1% |
| Q1 2021 | $37,050,000 | -54.2% | 3,750,000 | +7.1% | 0.66% | -62.2% |
| Q4 2020 | $80,815,000 | +43.1% | 3,500,000 | -12.5% | 1.74% | +26.5% |
| Q3 2020 | $56,480,000 | -16.8% | 4,000,000 | -11.1% | 1.37% | -27.8% |
| Q2 2020 | $67,860,000 | +22.4% | 4,500,000 | -25.0% | 1.90% | -18.9% |
| Q1 2020 | $55,440,000 | +62.6% | 6,000,000 | +71.4% | 2.34% | +77.8% |
| Q4 2019 | $34,090,000 | +41.7% | 3,500,000 | +16.7% | 1.32% | +36.5% |
| Q3 2019 | $24,060,000 | -22.9% | 3,000,000 | +20.0% | 0.96% | -23.5% |
| Q2 2019 | $31,200,000 | -26.0% | 2,500,000 | -19.4% | 1.26% | -26.7% |
| Q1 2019 | $42,160,000 | +25.7% | 3,100,000 | -11.4% | 1.72% | +38.8% |
| Q4 2018 | $33,530,000 | -44.5% | 3,500,000 | -30.0% | 1.24% | -21.1% |
| Q3 2018 | $60,450,000 | +13.8% | 5,000,000 | +47.1% | 1.57% | +39.3% |
| Q2 2018 | $53,108,000 | +3.9% | 3,400,000 | 0.0% | 1.13% | +76.4% |
| Q1 2018 | $51,136,000 | +48.1% | 3,400,000 | +41.7% | 0.64% | +22.8% |
| Q4 2017 | $34,536,000 | +34.7% | 2,400,000 | +41.2% | 0.52% | +17.9% |
| Q3 2017 | $25,636,000 | +34.0% | 1,700,000 | -10.5% | 0.44% | +32.3% |
| Q2 2017 | $19,133,000 | +41.2% | 1,900,000 | 0.0% | 0.33% | +11.0% |
| Q1 2017 | $13,547,000 | +13.6% | 1,900,000 | -20.8% | 0.30% | +13.6% |
| Q4 2016 | $11,929,000 | -36.8% | 2,400,000 | -5.9% | 0.26% | -29.0% |
| Q3 2016 | $18,870,000 | +176.5% | 2,550,000 | +104.0% | 0.37% | +164.5% |
| Q2 2016 | $6,825,000 | – | 1,250,000 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |